



Incyte to Host Conference Call to Discuss Clinical Results From a Phase II Study of Reverset in HIV-Infected Patients

February 11, 2004

WILMINGTON, Del.--Feb. 11, 2004--

Call Scheduled For Thursday February 12, 2004 - 8:30 a.m. ET/5:30 a.m. PT

Incyte Corporation (Nasdaq:INCY) announced today that it will host a conference call on Thursday, February 12, 2004 to discuss the clinical results from a Phase II study of Reverset(TM) in treatment-naïve human immunodeficiency virus (HIV)-infected patients.

The schedule for the conference call is as follows:

- Reverset Conference Call: 8:30 a.m. ET Thursday, Feb.12
- Domestic Dial In Number: 877-692-2592
- International Dial In Number: 973-582-2700
- Conference call ID # 4474023

Slides accompanying the call, as well as a webcast of the audio portion of the call, will be webcast live on CCBN and can be accessed at: www.incyte.com/webcasts.

If you are unable to participate, a replay of the conference call will be available through March 1, 2004 (12:00 midnight ET). The replay dial-in number for the U.S. is 877-519-4471 and dial-in number for international callers is 973-341-3080. The replay pin number is 4474023 or access the replay on Incyte's website.

About Incyte

Incyte is a Wilmington, Delaware-based drug discovery and development company with a growing pipeline of novel small molecule drugs to treat HIV, inflammation, cancer and diabetes. The company's most advanced product candidate, Reverset, is an oral, once-a-day therapy in Phase II clinical trials to treat patients with HIV infections. Currently, Incyte has four drug discovery programs underway, an extensive intellectual property portfolio and a proteomic information business based in Beverly, Massachusetts.

CONTACT:

Incyte Corporation, Wilmington
Pamela M. Murphy, 302-498-6944
pmurphy@incyte.com

SOURCE: Incyte Corporation